Evidence map›Paper›PMID 40678072›Full record

ArticleFrontiers in oncology2025

FN1 from cancer-associated fibroblasts orchestrates pancreatic cancer metastasis via integrin-PI3K/AKT signaling.

Xianguang Zhu, Yanwei Li, Huifang Liu, Zheng Xiao

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. ADAMTS14 is a novel modulator of fibroblast mechanoactivation in pulmonary fibrosis.American journal of respiratory and critical care medicine · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xianguang ZhuDepartment of Clinical Laboratory, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, and People's Hospital of Henan University, Zhengzhou, Henan, China.
Yanwei LiDepartment of Pathology, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Huifang LiuDepartment of Clinical Laboratory, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, and People's Hospital of Henan University, Zhengzhou, Henan, China.
Zheng XiaoDepartment of Clinical Laboratory, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, and People's Hospital of Henan University, Zhengzhou, Henan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The metastasis of pancreatic ductal adenocarcinoma (PDAC) is closely linked to the remodeling of cancer-associated fibroblasts (CAFs) within the tumor microenvironment (TME), though the precise molecular mechanisms remain unclear. This study aims to elucidate the role of CAFs in PDAC metastasis. Methods: We integrated transcriptomic (GSE183795) and single-cell sequencing data (GSE156405) to screen for core genes associated with PDAC. Results: Multi-omics analysis identified FN1 as a pivotal hub gene in the PI3K pathway, highly expressed in metastatic CAF subsets. Conclusion: FN1 directly drives PDAC metastasis via the integrin-PI3K/AKT axis and indirectly promotes a "cold tumor" microenvironment by recruiting immunosuppressive cells. This dual role of FN1 enhances our understanding of CAFs heterogeneity and offers novel therapeutic strategies for PDAC.

Indexed as

cancer-associated fibroblastsfibronectin 1integrin-PI3K/AKT signaling axismetastasispancreatic cancer

Identifiers

PMID40678072
PMCPMC12267018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.